Propofol Cardioprotection for Type II Diabetics

NCT ID: NCT00734383

Last Updated: 2012-07-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 137 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-04-30
• Study Completion Date: 2012-06-30

Brief Summary

The purpose of this study is to determine if an intravenous anesthetic with antioxidant properties will protect the heart of diabetic patients from injury while undergoing coronary bypass surgery.

Detailed Description

Diabetic patients are at elevated risk for low cardiac output syndrome. This high risk scenario adversely affects up to 26% of patients recovering from cardiac surgery. Aggressive hemodynamic treatments are required, but can prove inadequate. Low cardiac output syndrome can quadruple the overall mortality rate for aortocoronary bypass surgery from 2% to 8%. Therefore, an urgent need exists for effective forms of preemptive cardioprotection and antioxidant protection may play a crucial role. Our research into the therapeutic potential of propofol, an intravenous anesthetic with antioxidant properties, could have significant impact on outcome in this select population. The proposed study represents a novel therapeutic approach for the prevention of myocardial ischemia-reperfusion injury in diabetic patients undergoing cardiac surgery with cardiopulmonary bypass.

RESEARCH PLAN

Two blinded, randomized controlled phase II studies will be conducted in patients undergoing primary aortocoronary bypass surgery.

STUDY A

Specific Aims:

1. To determine whether propofol increases nitric oxide bioavailability and decreases ET-1 formation in diabetic patients undergoing aortocoronary bypass surgery

2. To determine whether propofol inhibits superoxide formation or downregulates iNOS gene expression in cardiac tissue.

Hypothesis:

Oxidant stress during myocardial reperfusion promotes the conversion of NO to the cardiotoxic free radical, peroxynitrite, and enhances the formation of the vasoconstrictor ET-1 in diabetic patients. We postulate that these factors cause postoperative cardiac dysfunction of the ischemic-reperfused diabetic heart.

STUDY B

Specific Aim:

To determine whether a high dose of intravenous insulin increases the effect of propofol on perioperative oxidative stress.

Hypothesis: Insulin, by preventing hyperglycemia, enhances propofol's effect on oxidative stress.

Methods

In Study A, 144 patients (72 patients with Type II DM + 72 patients with no DM) will be randomized to receive either propofol 120 ug/kg/min or isoflurane 0.5 to 2% for a treatment interval of 120 to 150 min (10 min before and during CPB, and for 15 min following aortic declamping). All patients will receive a continuous intravenous (I.V.) infusion of insulin as needed to maintain glucose levels at 8 to 12 mmol/L.

In Study B, 72 Type II diabetic patients will be randomized to isoflurane or propofol cardioprotection. All patients will be treated with the perioperative hyperinsulinemic clamp to maintain blood glucose levels within a target range of 4.5 - 6 mmol/L for up to 6 hours following release of aortic crossclamp.

Arterial and coronary sinus blood will be sampled simultaneously before initiation of CPB and at 5 min reperfusion for Troponin I, 15-F2t-isoP, nitrotyrosine and tyrosine, ET-1, and TNF-alpha. An index of myocardial derived 15-F2t-isoP and peroxynitrite will be determined from the Cs-Ao difference in percentage ratio of plasma free 15-F2t-isoP and nitrotyrosine to tyrosine, respectively.

Atrial tissue will be sampled before initiation of CPB and at 15min reperfusion for detection of iNOS, eNOS and superoxide formation. This will coincide with central venous blood sampling for measurement of the concentration of propofol.

The levels of 15-F2t-isoP, nitrotyrosine and tyrosine, ET-1, and TNF-alpha in blood will be determined at 2 hours postoperatively. Troponin I levels will be determined at 2, 12, and 24 hours postoperatively. Cardiac function will be assessed up to 6 hours postoperatively by pulmonary artery catheter and transesophageal echocardiography.

This study represents a novel therapeutic approach for the prevention of myocardial ischemia-reperfusion injury. This study on diabetic patients will provide the prerequisite knowledge for a randomized clinical trial powered to detect clinical outcomes in this high risk patient population.

Conditions

Myocardial Injury

Keywords

coronary artery bypass surgery; coronary artery bypass grafting; cardiopulmonary bypass; diabetes; myocardial injury markers,; sex differences; cardiac anesthesia; inhalational anesthetics

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1

Propofol Cardioprotection

Group Type: EXPERIMENTAL

Propofol

Intervention Type: DRUG

Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).

2

Volatile Anesthesia Preconditioning

Group Type: EXPERIMENTAL

Propofol

Intervention Type: DRUG

Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.

Interventions

Propofol

Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).

Intervention Type: DRUG

Propofol

Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients with and without Type II Diabetes Mellitus

2. Hemodynamically Stable

3. Non urgent Coronary Bypass Grafting utilizing Cardiopulmonary Bypass

Exclusion Criteria

1. Age less than 18 or greater than 80 years of age

2. refuse informed consent

3. Co-existing valvular heart disease

4. Acute or evolving myocardial infarction

5. hypersensitivity to propofol or formulation component

6. Use of NSAIDs, Vitamins C or E within 5 to 7 days of surgery

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 29 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role: collaborator

University of British Columbia

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David M. Ansley, MD

Role: PRINCIPAL_INVESTIGATOR

University of British Columbia

Peter T. Choi, MD

Role: STUDY_DIRECTOR

University of British Columbia

David DY Chen, Ph.D

Role: STUDY_DIRECTOR

University of British Columbia

Locations

UBC Dept of Anesthesiology, Pharmacology & Therapeutics, Vancouver Acute Hospital

Vancouver, British Columbia, Canada

Countries

Canada

References

Ansley DM, Raedschelders K, Choi PT, Wang B, Cook RC, Chen DD. Propofol cardioprotection for on-pump aortocoronary bypass surgery in patients with type 2 diabetes mellitus (PRO-TECT II): a phase 2 randomized-controlled trial. Can J Anaesth. 2016 Apr;63(4):442-53. doi: 10.1007/s12630-015-0580-z. Epub 2015 Dec 31.

Reference Type: DERIVED

PMID: 26721648 (View on PubMed)

Other Identifiers

H04-70456

Identifier Type: -

Identifier Source: org_study_id